Impact of Thyroid Hormones on Human Glucose and Energy Metabolism

Condition(s) studied

Investigational drug(s) / intervention(s)

Oral Glucose Tolerance Test: Participants will receive a 75 g oral glucose tolerance (3h) before the start of treatment, two weeks and three months after start of treatment. Body composition will measured by bioimpedance analysis. Before and during the oral glucose tolerance test, indirect calometry will assess metabolic flexibility.

Study summary

The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism.

Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.

Eligibility

Primary outcome measure(s)

• Insulin sensitivity — Baseline, 2 weeks, 3 months
  Effect of changes in thyroid hormone levels on whole-body insulin sensitivity, assessed from glucose and insulin measurements during the 75 g oral glucose tolerance test.
• Insulin secretion — Baseline, 2 weeks, 3 months
  Effect of changes in thyroid hormone levels on insulin secretion, assessed from glucose and insulin/c-peptide measurements during the 75 g oral glucose tolerance test.

Trial sites (1)

More University of Ulm trials in Germany